This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewis, J. J. Articles by Brennan, M. F. Search for Related Content PubMed PubMed Citation Articles by Lewis, J. J. Articles by Brennan, M. F. Social Bookmarking                            What's this?

Synovial Sarcoma: A Multivariate Analysis of Prognostic Factors in 112 Patients With Primary Localized Tumors of the Extremity

From the Departments of Surgery, Biostatistics, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Jonathan J. Lewis, MD, PhD, Memorial Sloan-Kettering Cancer Center, Department of Surgery, 1275 York Ave, New York, NY 10021; email lewisj{at}mkcc.org

PURPOSE: Synovial sarcoma is a high-grade tumor that is associated with poor prognosis. Previous studies analyzing prognostic factors are limited because of inclusion of heterogeneous cohorts of patients with nonextremity and recurrent tumors. The objective of this study was to determine independent prognostic factors of primary synovial sarcoma localized to the extremity.

PATIENTS AND METHODS: Between July 1, 1982, and June 30, 1996, 112 patients underwent surgical resection for cure at our institution and then were followed-up prospectively. Clinical and pathologic factors examined for prognostic value included age, sex, tumor site and location, depth, size, microscopic status of surgical margins, invasion of bone or neurovascular structures, and monophasic or biphasic histology. The end points analyzed were the time to first local recurrence that was not preceded by a distant recurrence, time to any distant recurrence, and time to disease-related mortality. These end points were modeled using the method of Kaplan and Meier and analyzed by the log-rank test and Cox regression.

RESULTS: The median duration of follow-up among survivors in this cohort of 112 patients was 72 months. The 5-year local-recurrence, distant-recurrence, and mortality rates were 12%, 39%, and 25%, respectively. Tumor size 5 cm (P = .001; relative risk [RR] = 2.7; 95% confidence interval [CI], 1.5 to 5.2) and the presence of bone or neurovascular invasion (P = .04; RR = 2.3; 95% CI, 1.0 to 5.3) were independent adverse predictors of distant recurrence. Tumor size 5 cm (P = .003; RR = 2.3; 95% CI, 1.4 to 6.3) and the presence of bone or neurovascular invasion (P = .03; RR = 2.7; 95% CI, 1.0 to 6.5) were also independent adverse predictors of mortality.

CONCLUSION: The natural history of primary synovial sarcoma of the extremity is related to tumor size and invasion of bone and neurovascular structures.

Presented in part at the Thirty-Third Annual Meeting of the American Society of Clinical Oncology, Denver, CO, May 17-20, 1997.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Italiano, N. Penel, Y.-M. Robin, B. Bui, A. Le Cesne, S. Piperno-Neumann, M. Tubiana-Hulin, E. Bompas, C. Chevreau, N. Isambert, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group Ann. Onc., March 1, 2009; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]

				R. J. Canter, L.-X. Qin, R. G. Maki, M. F. Brennan, M. Ladanyi, and S. Singer A Synovial Sarcoma-Specific Preoperative Nomogram Supports a Survival Benefit to Ifosfamide-Based Chemotherapy and Improves Risk Stratification for Patients Clin. Cancer Res., December 15, 2008; 14(24): 8191 - 8197. [Abstract] [Full Text] [PDF]

				B. W. Scheithauer, A. I. Silva, K. Kattner, J. Seibly, A. M. Oliveira, and K. Kovacs Synovial sarcoma of the sellar region Neuro-oncol, October 1, 2007; 9(4): 454 - 459. [Abstract] [Full Text] [PDF]

				M. D. Murphey, M. S. Gibson, B. T. Jennings, A. M. Crespo-Rodriguez, J. Fanburg-Smith, and D. A. Gajewski From the Archives of the AFIP: Imaging of Synovial Sarcoma with Radiologic-Pathologic Correlation RadioGraphics, September 1, 2006; 26(5): 1543 - 1565. [Abstract] [Full Text] [PDF]

				J. Terry, J. M. Lubieniecka, W. Kwan, S. Liu, and T. O. Nielsen Hsp90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Prevents Synovial Sarcoma Proliferation via Apoptosis in In vitro Models Clin. Cancer Res., August 1, 2005; 11(15): 5631 - 5638. [Abstract] [Full Text] [PDF]

				T. Ishibe, T. Nakayama, T. Okamoto, T. Aoyama, K. Nishijo, K. R. Shibata, Y. Shima, S. Nagayama, T. Katagiri, Y. Nakamura, et al. Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to Molecular Target Therapy Clin. Cancer Res., April 1, 2005; 11(7): 2702 - 2712. [Abstract] [Full Text] [PDF]

				E. L. Spurrell, C. Fisher, J. M. Thomas, and I. R. Judson Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital Ann. Onc., March 1, 2005; 16(3): 437 - 444. [Abstract] [Full Text] [PDF]

				L. Guillou, J. Benhattar, F. Bonichon, G. Gallagher, P. Terrier, E. Stauffer, N. de Saint Aubain Somerhausen, J.-J. Michels, G. Jundt, D. R. Vince, et al. Histologic Grade, But Not SYT-SSX Fusion Type, Is an Important Prognostic Factor in Patients With Synovial Sarcoma: A Multicenter, Retrospective Analysis J. Clin. Oncol., October 15, 2004; 22(20): 4040 - 4050. [Abstract] [Full Text] [PDF]

				M. F. Okcu, M. Munsell, J. Treuner, A. Mattke, A. Pappo, A. Cain, A. Ferrari, M. Casanova, A. Ozkan, and B. Raney Synovial Sarcoma of Childhood and Adolescence: A Multicenter, Multivariate Analysis of Outcome J. Clin. Oncol., April 15, 2003; 21(8): 1602 - 1611. [Abstract] [Full Text] [PDF]

				S. V. Allander, P. B. Illei, Y. Chen, C. R. Antonescu, M. Bittner, M. Ladanyi, and P. S. Meltzer Expression Profiling of Synovial Sarcoma by cDNA Microarrays : Association of ERBB2, IGFBP2, and ELF3 with Epithelial Differentiation Am. J. Pathol., November 1, 2002; 161(5): 1587 - 1595. [Abstract] [Full Text] [PDF]

				M. Ladanyi, C. R. Antonescu, D. H. Leung, J. M. Woodruff, A. Kawai, J. H. Healey, M. F. Brennan, J. A. Bridge, J. R. Neff, F. G. Barr, et al. Impact of SYT-SSX Fusion Type on the Clinical Behavior of Synovial Sarcoma: A Multi-Institutional Retrospective Study of 243 Patients Cancer Res., January 1, 2002; 62(1): 135 - 140. [Abstract] [Full Text] [PDF]